Navigation Links
BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy
Date:8/6/2014

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto  contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the Company's Phase 3 pivotal and safety studies of Clonidine Topical Gel) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  The BioDelivery Sciences logo and BUNAVAIL™ are trademarks owned by BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
2. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
3. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
8. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. BioDelivery Sciences Announces $40 Million Registered Financing
10. BioDelivery Sciences Announces Completion of BNX Safety Study
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
(Date:9/19/2014)... 19, 2014) - New research published today in the ... cases could reach 6,800 in West Africa by the ... not enacted. , Arizona State University and Harvard ... rate of rise in cases significantly increased in August ... mass quarantine was put in place, indicating that the ...
(Date:9/19/2014)... September 19, 2014 Famous Vancouver company, ... that it has now become a one-stop-solution for heating, ... businesses in Vancouver. The company has achieved this status ... to its customers. While there are many companies that ... have a single vendor who can offer all of ...
(Date:9/19/2014)... Recently, Top10BestSEOHosting.com has compared many ... IX Web Hosting and Bluehost are the best ... known to most people, VPS (Virtual Private Server) ... computer into many servers, each of which has ... own dedicated computer,” the manager of Top10BestSEOHosting.com says. ...
(Date:9/19/2014)... Top 10 Best SEO Hosting, a leading ... and Bluehost are among the best web hosting ... recommended suppliers for webmasters from the USA, UK, ... Linux hosting (including VPS and cloud hosting). , ... top hosting companies that started thinking Green. The ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Ticket Down ... tickets for her 2015 “Honeymoon” Tour. This popular ... for additional savings at the checkout. , Ariana Grande 2015 ... (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI (BMO ... (Xcel Energy Center) , March 03, 2015: Chicago, IL (Allstate ...
Breaking Medicine News(10 mins):Health News:Research predicts possible 6,800 new Ebola cases this month 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4
... will target women and highlight product,s efficacy, ease ... 21 Watson Pharmaceuticals, a leader ... the launch of GELNIQUE(TM) (oxybutynin chloride) gel 10%, ... of overactive bladder (OAB) with symptoms of urge ...
... May 21 Go Healthy, Inc. (Pink Sheets: GOHE) ... endorsement from District Five of the Texas Chiropractic Association. ... Director of District Five of the T.C.A., mentions positive ... the customer service rendered to the Association,s members. ...
... Sullivan,s Web Conference on the current global situationLONDON, May ... airlines will be discussed during a web conference that ... at 4 pm BST.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... analyse the current global situation and take a first ...
... Contribution Mark to Support Families Living with Autism and Other Disabilities ... ... Safeway (NYSE:SWY) captures Easter Seals, highest honor ... children and adults with autism and other disabilities in 2009 alone ...
... fit horizontal tummy tuck and c-section scars. It is made with FDA ... to last 1-3 days. It can be applied and removed whenever you ... ... innovative new company specializing in adhesive products used to conceal scars, last ...
... the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones. , ... ... -- NuSil Technology ( http://www.nusil.com ), a leading formulator and ... announced a definitive agreement to acquire the pharmaceutical Antifoam (Simethicone) ...
Cached Medicine News:Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 2Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 3Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 4Health News:Go Healthy Receives Letter of Endorsement from the Texas Chiropractic Association, District Five State Director - Dr. Thomas Klesmit 2Health News:Airlines in Turbulence - Virus Outbreaks and their Impact on the Aviation Market 2Health News:Airlines in Turbulence - Virus Outbreaks and their Impact on the Aviation Market 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: